Changeflow GovPing Pharma & Drug Safety Polyglutamated Antifolates and Uses Thereof (EP...
Routine Notice Added Final

Polyglutamated Antifolates and Uses Thereof (EP3496757A1)

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3496757A1 for polyglutamated antifolates and their therapeutic uses, filed by L.E.A.F Holdings Group LLC. The patent covers compositions for treating cancer and inflammatory conditions. The application was published April 8, 2026, designating 36 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states. No compliance deadlines or penalties are specified.

What changed

The EPO published patent application EP3496757A1 for polyglutamated antifolates and their uses in treating cancer and inflammatory diseases. The application covers pharmaceutical compositions containing antifolate compounds, including claims related to drug formulations and therapeutic methods. Inventors include Clet Niyikiza and Victor Mandla Moyo.

Affected parties in designated EU states should monitor the progression of this patent application through grant proceedings. Pharmaceutical companies developing antifolate-based therapeutics may need to evaluate freedom-to-operate considerations. Research institutions conducting related work should assess potential licensing needs if the patent proceeds to grant.

What to do next

  1. Monitor for patent grant proceedings
  2. Review licensing opportunities if operating in designated EU states

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

POLYGLUTAMATED ANTIFOLATES AND USES THEREOF

Publication EP3496757A1 Kind: A1 Apr 08, 2026

Applicants

L.E.A.F Holdings Group LLC

Inventors

NIYIKIZA, Clet, MOYO, Victor, Mandla

IPC Classifications

A61K 9/12 20060101AFI20260302BHEP A61K 45/06 20060101ALI20260302BHEP A61P 35/00 20060101ALI20260302BHEP A61K 31/517 20060101ALI20260302BHEP A61K 31/519 20060101ALI20260302BHEP A61K 47/64 20170101ALI20260302BHEP A61P 19/02 20060101ALI20260302BHEP C07K 16/28 20060101ALI20260302BHEP A61K 47/68 20170101ALI20260302BHEP A61K 47/69 20170101ALI20260302BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3496757A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication Pharmaceutical licensing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!